Form 8-K

Send us Feedback

ViroPharma (VPHM)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

Annual Reports

Quarterly Reports

8-K

8-K (Jan 9, 2013)8-K (Jan 7, 2013)8-K (Jan 4, 2013)8-K (Dec 12, 2012)8-K (Oct 25, 2012)8-K (Oct 3, 2012)8-K (Sep 25, 2012)8-K (Sep 21, 2012)8-K (Aug 31, 2012)8-K (Aug 22, 2012)8-K (Aug 9, 2012)8-K (Aug 6, 2012)8-K (Aug 1, 2012)8-K (Jun 22, 2012)8-K (May 23, 2012)8-K (May 18, 2012)8-K (May 1, 2012)8-K (Apr 24, 2012)8-K (Apr 13, 2012)8-K (Apr 10, 2012)8-K (Mar 2, 2012)8-K (Feb 28, 2012)8-K (Feb 7, 2012)8-K (Jan 6, 2012)8-K (Jan 5, 2012)8-K (Jan 4, 2012)8-K (Dec 23, 2011)8-K (Dec 14, 2011)8-K (Dec 6, 2011)8-K (Nov 15, 2011)8-K (Nov 7, 2011)8-K (Oct 27, 2011)8-K (Sep 30, 2011)8-K (Sep 15, 2011)8-K (Sep 13, 2011)8-K (Sep 9, 2011)8-K (Sep 6, 2011)8-K (Jul 28, 2011)8-K (Jun 24, 2011)8-K (Jun 15, 2011)8-K (May 31, 2011)8-K (May 26, 2011)8-K (May 24, 2011)8-K (May 11, 2011)8-K (Apr 28, 2011)8-K (Apr 15, 2011)8-K (Mar 18, 2011)8-K (Mar 9, 2011)8-K (Feb 24, 2011)8-K (Jan 10, 2011)8-K (Jan 7, 2011)8-K (Dec 17, 2010)8-K (Oct 27, 2010)8-K (Oct 22, 2010)8-K (Sep 10, 2010)8-K (Jul 28, 2010)8-K (Jun 21, 2010)8-K (May 26, 2010)8-K (May 25, 2010)8-K (Apr 28, 2010)8-K (Apr 27, 2010)8-K (Mar 31, 2010)8-K (Mar 24, 2010)8-K (Mar 4, 2010)8-K (Mar 2, 2010)8-K (Feb 24, 2010)8-K (Feb 10, 2010)8-K (Jan 11, 2010)8-K (Jan 8, 2010)8-K (Oct 28, 2009)8-K (Oct 23, 2009)8-K (Aug 5, 2009)8-K (Jul 29, 2009)8-K (Jul 15, 2009)8-K (Jun 23, 2009)8-K (Jun 17, 2009)8-K (Jun 8, 2009)8-K (Jun 4, 2009)8-K (May 29, 2009)8-K (May 26, 2009)8-K (Apr 29, 2009)8-K (Mar 24, 2009)8-K (Mar 18, 2009)8-K (Feb 27, 2009)8-K (Feb 24, 2009)8-K (Feb 13, 2009)8-K (Feb 9, 2009)8-K (Feb 3, 2009)8-K (Jan 14, 2009)8-K (Dec 23, 2008)8-K (Dec 18, 2008)8-K (Dec 16, 2008)8-K (Dec 2, 2008)8-K (Nov 14, 2008)8-K (Oct 29, 2008)8-K (Oct 24, 2008)8-K (Oct 21, 2008)8-K (Oct 14, 2008)8-K (Sep 12, 2008)8-K (Sep 3, 2008)8-K (Jul 30, 2008)8-K (Jul 18, 2008)8-K (Jul 15, 2008)8-K (May 29, 2008)8-K (May 28, 2008)8-K (May 20, 2008)8-K (Apr 30, 2008)8-K (Apr 18, 2008)8-K (Apr 17, 2008)8-K (Apr 11, 2008)8-K (Apr 3, 2008)8-K (Mar 20, 2008)8-K (Feb 27, 2008)8-K (Feb 26, 2008)8-K (Jan 9, 2008)8-K (Jan 8, 2008)8-K (Oct 30, 2007)8-K (Aug 10, 2007)8-K (Aug 1, 2007)8-K (May 2, 2007)8-K (Apr 16, 2007)8-K (Mar 26, 2007)8-K (Mar 21, 2007)8-K (Feb 28, 2007)8-K (Feb 7, 2007)8-K (Jan 8, 2007)8-K (Dec 29, 2006)8-K (Nov 2, 2006)8-K (Oct 25, 2006)8-K (Sep 20, 2006)8-K (Aug 29, 2006)8-K (Aug 14, 2006)8-K (Aug 2, 2006)8-K (Jul 3, 2006)8-K (Jun 1, 2006)8-K (May 22, 2006)8-K (May 19, 2006)8-K (May 4, 2006)8-K (Apr 19, 2006)8-K (Mar 30, 2006)8-K (Mar 22, 2006)8-K (Feb 28, 2006)8-K (Jan 26, 2006)8-K (Jan 23, 2006)8-K (Jan 18, 2006)8-K (Dec 7, 2005)8-K (Dec 1, 2005)8-K (Nov 29, 2005)8-K (Nov 10, 2005)8-K (Nov 7, 2005)8-K (Nov 3, 2005)8-K (Aug 15, 2005)8-K (Aug 3, 2005)8-K (Jul 13, 2005)8-K (Jul 6, 2005)8-K (Jun 29, 2005)8-K (Jun 20, 2005)8-K (Jun 15, 2005)8-K (Jun 13, 2005)8-K (Jun 7, 2005)8-K (Jun 1, 2005)8-K (May 31, 2005)8-K (May 24, 2005)8-K (May 10, 2005)8-K (May 3, 2005)8-K (Apr 8, 2005)8-K (Apr 6, 2005)8-K (Mar 29, 2005)8-K (Mar 15, 2005)8-K (Mar 11, 2005)8-K (Mar 3, 2005)8-K (Feb 23, 2005)8-K (Feb 15, 2005)8-K (Jan 25, 2005)8-K (Jan 13, 2005)8-K (Dec 23, 2004)8-K (Nov 29, 2004)8-K (Nov 24, 2004)8-K (Nov 10, 2004)8-K (Nov 5, 2004)8-K (Nov 3, 2004)8-K (Oct 19, 2004)8-K (Oct 18, 2004)8-K (Sep 15, 2004)8-K (Aug 23, 2004)8-K (Aug 6, 2004)8-K (Jun 28, 2004)8-K (May 26, 2004)8-K (May 25, 2004)8-K (May 4, 2004)8-K (Mar 18, 2004)8-K (Feb 26, 2004)8-K (Feb 25, 2004)8-K (Feb 6, 2004)8-K (Jan 20, 2004)8-K (Dec 19, 2003)8-K (Dec 3, 2003)8-K (Nov 26, 2003)8-K (Nov 7, 2003)8-K (Oct 2, 2003)8-K (Aug 15, 2003)8-K (Aug 12, 2003)8-K (Aug 1, 2003)8-K (Jul 31, 2003)8-K (Jul 16, 2003)8-K (Jul 1, 2003)8-K (May 9, 2003)8-K (May 8, 2003)8-K (Mar 25, 2003)8-K (Feb 27, 2003)8-K (Feb 24, 2003)8-K (Jan 3, 2003)8-K (Oct 31, 2002)8-K (Aug 28, 2002)8-K (Aug 1, 2002)8-K (Jun 25, 2002)8-K (Jun 5, 2002)8-K (May 10, 2002)8-K (May 2, 2002)8-K (Mar 29, 2002)8-K (Mar 20, 2002)8-K (Feb 15, 2002)8-K (Feb 14, 2002)8-K (Dec 21, 2001)8-K (Nov 15, 2001)8-K (Nov 13, 2001)8-K (Oct 30, 2001)8-K (Oct 19, 2001)8-K (Sep 10, 2001)8-K (Jul 31, 2001)8-K (Jul 27, 2001)8-K (May 30, 2001)8-K (Apr 26, 2001)8-K (Mar 16, 2001)8-K (Mar 15, 2001)8-K (Mar 1, 2001)8-K (Feb 27, 2001)8-K (Feb 15, 2001)8-K (Feb 13, 2001)8-K (Jan 9, 2001)8-K (Nov 28, 2000)8-K (Nov 15, 2000)8-K (Oct 30, 2000)8-K (Oct 25, 2000)8-K (Oct 17, 2000)8-K (Oct 10, 2000)8-K (Aug 30, 2000)8-K (Aug 23, 2000)8-K (Aug 21, 2000)8-K (Jul 28, 2000)8-K (Jul 7, 2000)8-K (May 26, 2000)8-K (Apr 11, 2000)8-K (Feb 25, 2000)8-K (Feb 16, 2000)8-K (Sep 21, 1998)

Other

ViroPharma 8-K 2007

Documents found in this filing:

Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 2, 2007

VIROPHARMA INCORPORATED

(Exact Name of Registrant as Specified in its Charter)

DELAWARE

0-021699

23-2789550

(State or Other Jurisdiction of

Incorporation or Organization)

(Commission File Number)

(I.R.S. Employer

Identification Number)

397 EAGLEVIEW BOULEVARD, EXTON, PENNSYLVANIA 19341

(Address of Principal Executive Offices including Zip Code)

(610) 458-7300

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

Item 2.02 Results of Financial Operations and Financial Condition.

On May 2, 2007, ViroPharma Incorporated (the “Company”) issued a press release announcing its financial results for its first quarter ended March 31, 2007. A copy of the press release is set forth as Exhibit 99.1 attached hereto.

Item 7.01 Regulation FD Disclosure.

On May 1, 2007, the Company announced the decision to establish a wholly owned European subsidiary to execute on the European regulatory strategy and commercialization of maribavir, the Company’s oral antiviral drug candidate targeting cytomegalovirus, without a strategic partner. A copy of the press release is set forth as Exhibit 99.2 attached hereto.

Additionally, the Company announced that Robert Pietrusko, Pharm. D. has joined the company as vice president of global regulatory affairs and quality and as a member of the management team.

Item 9.01 Financial Statements and Exhibits.

The following exhibits are attached to this Form 8-K:


(d)	Exhibit No.	Description

	99.1	Press release dated May 2, 2007 announcing financial results.

	99.2	Press release dated May 1, 2007 announcing European subsidiary.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	VIROPHARMA INCORPORATED

Date: May 2, 2007	By:	/s/ Thomas F. Doyle
		Thomas F. Doyle
		Vice President, General Counsel and Secretary

Index of Exhibits


Exhibit Number		Description
99.1		Press release dated May 2, 2007 announcing financial results.

99.2		Press release dated May 1, 2007 announcing European subsidiary.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

Mobile | Advertise | Licensing & Partnerships | Blogger Tools | Jobs

ViroPharma (VPHM)

Annual Reports

Quarterly Reports

8-K

Other

Documents found in this filing: